JPMorgan upgrades RXO to Neutral and raises price target to $30 amid C.H. Robinson acquisition
JPMorgan moved RXO Inc. from Underweight to Neutral and lifted its price target from $22 to $30 following C.H. Robinson Worldwide's announcement to acquire the company. The analyst cited expected $300 million of net cost synergies and a gross profit margin of 14.91% over the last twelve months. The stock is trading near $28.60, close to the new target. JPMorgan expects the deal to close in the first half of 2027.
Why it matters
JPMorgan’s upgrade signals a more favorable valuation for RXO, which could attract buying interest and support the share price toward the $30 target. The projected synergies suggest potential margin improvement for the combined business.
Key facts
- 1JPMorgan upgraded RXO from Underweight to Neutral. investing.com
- 2JPMorgan raised the price target to $30 from $22. investing.com
- 3RXO is trading at $28.65. investing.com
- 4C.H. Robinson announced a definitive agreement to acquire RXO. investing.com
- 5The acquisition is expected to deliver $300 million in net cost synergies. investing.com
- 6RXO’s gross profit margin was 14.91% in the last twelve months. investing.com
Open questions
- Year‑to‑date and one‑year performance figures differ between materials 2 and 3.
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.